Innovation in myeloma treatments PARP excellence!

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this issue of Blood, Neri and colleagues report a promising treatment of myeloma using a combination of bortezomib plus inhibition of the enzyme PARP1 (REF). 1This is welcome news, as new avenues for the treatment of the disease are needed.

Original languageEnglish (US)
Pages (from-to)6234-6235
Number of pages2
JournalBlood
Volume118
Issue number24
DOIs
StatePublished - Dec 8 2011

Fingerprint

Blood
Innovation
Enzymes
Bortezomib

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Innovation in myeloma treatments PARP excellence! / Fonseca, Rafael.

In: Blood, Vol. 118, No. 24, 08.12.2011, p. 6234-6235.

Research output: Contribution to journalArticle

Fonseca, Rafael. / Innovation in myeloma treatments PARP excellence!. In: Blood. 2011 ; Vol. 118, No. 24. pp. 6234-6235.
@article{ac4ab1f80a0c46bbbcc7606e38ecc4e6,
title = "Innovation in myeloma treatments PARP excellence!",
abstract = "In this issue of Blood, Neri and colleagues report a promising treatment of myeloma using a combination of bortezomib plus inhibition of the enzyme PARP1 (REF). 1This is welcome news, as new avenues for the treatment of the disease are needed.",
author = "Rafael Fonseca",
year = "2011",
month = "12",
day = "8",
doi = "10.1182/blood-2011-10-381129",
language = "English (US)",
volume = "118",
pages = "6234--6235",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "24",

}

TY - JOUR

T1 - Innovation in myeloma treatments PARP excellence!

AU - Fonseca, Rafael

PY - 2011/12/8

Y1 - 2011/12/8

N2 - In this issue of Blood, Neri and colleagues report a promising treatment of myeloma using a combination of bortezomib plus inhibition of the enzyme PARP1 (REF). 1This is welcome news, as new avenues for the treatment of the disease are needed.

AB - In this issue of Blood, Neri and colleagues report a promising treatment of myeloma using a combination of bortezomib plus inhibition of the enzyme PARP1 (REF). 1This is welcome news, as new avenues for the treatment of the disease are needed.

UR - http://www.scopus.com/inward/record.url?scp=83455220284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455220284&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-10-381129

DO - 10.1182/blood-2011-10-381129

M3 - Article

C2 - 22161848

AN - SCOPUS:83455220284

VL - 118

SP - 6234

EP - 6235

JO - Blood

JF - Blood

SN - 0006-4971

IS - 24

ER -